BIGBEAR
PHARMACEUTICAL
Ivosidenib can reduce the production of the oncogenic metabolite 2-HG by selectively targeting and inhibiting the activity of the mutant IDH1 enzyme.
AuthenticGuaranteeFast DeliveryPrivacy Agios, a leading US-based cancer biopharmaceutical company and a pioneer in cellular metabolic therapies for cancer and rare genetic diseases, recentl···【More】
Update: 25 Mar,2026Source: BigbearViews: 91
The U.S. Food and Drug Administration (FDA) has approved TIBSOVO (ivosidenib) for the treatment of relapsed or refractory adult acute myeloid leukemia···【More】
Update: 25 Mar,2026Source: BigbearViews: 89
In 2021, Agios presented a comprehensive analysis of final data from the global Phase 3 ClarIDHy trial of the targeted anticancer drug ivosidenib (TIB···【More】
Update: 25 Mar,2026Source: BigbearViews: 89
On May 25, 2022, Servier announced that the U.S. FDA had approved ivosidenib (Tibsovo) in combination with azacitidine for the treatment of newly diag···【More】
Update: 25 Mar,2026Source: BigbearViews: 89
According to a press release from Servier Pharmaceuticals on October 24, the US Food and Drug Administration (FDA) announced that its IDH1 inhibitor T···【More】
Update: 25 Mar,2026Source: BigbearViews: 87
According to a press release from Servier Pharmaceuticals, the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the···【More】
Update: 25 Mar,2026Source: BigbearViews: 86
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
